- Report
- January 2026
- 190 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- July 2025
- 120 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- March 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 224 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- January 2026
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 375 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- November 2022
- 141 Pages
Global
From €4335EUR$4,950USD£3,763GBP
- Report
- March 2023
- 150 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- October 2023
- 183 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- April 2023
- 120 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- May 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- April 2023
- 117 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- April 2023
- 115 Pages
Global
From €4160EUR$4,750USD£3,611GBP
Hodgkin Lymphoma (HL) is a type of cancer that affects the lymphatic system, a part of the immune system. It is characterized by the presence of a type of cell called the Reed-Sternberg cell. HL is the most common type of lymphoma in the United States, and is most common in young adults. Treatment for HL typically involves chemotherapy, radiation therapy, and/or stem cell transplantation.
The oncology market for HL is highly competitive, with a number of companies offering treatments and therapies. These include pharmaceutical companies such as AbbVie, Bristol-Myers Squibb, and Merck; biotechnology companies such as Gilead Sciences and Celgene; and medical device companies such as Medtronic and Stryker. Show Less Read more
